Literature DB >> 6583305

Pharmacological basis of akinesia in Parkinson's disease.

H Narabayashi.   

Abstract

Akinesia, the core symptom of the parkinsonism, which is the term having been used routinely in daily practice of neurology in describing the specific motor disturbance in parkinsonian patients, is not well defined in sense of its generating mechanism. The author tried to analyze this concept from physiological and pharmacological standpoint and classified into three subgroups, i.e. slowness of movement, poverty of movement and difficulty in initiating repetitive movement. These three groups are interpreted as due to deficiency either of DA or of NE, the former being related to the slowness of movement and the poverty of movement and the latter to the freezing symptoms in the later stage of illness. Parkinson's disease now should better be understood as the result of deficiency of several catecholamine metabolites due to chains of enzymic error, and not only of DA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6583305

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.

Authors:  C Marin; E Aguilar; M Bonastre
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

2.  A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.

Authors:  R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Pavlovian conditioning of L-dopa induced movement.

Authors:  R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

5.  Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.

Authors:  V Pérez; C Marin; A Rubio; E Aguilar; M Barbanoj; J Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2009-08-27       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.